PMID- 11425459
OWN - NLM
STAT- MEDLINE
DCOM- 20010719
LR  - 20190816
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 127
IP  - 2
DP  - 2001 Jun
TI  - Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome 
      transforming to acute myeloid leukemia.
PG  - 174-6
AB  - A patient is described with myelodysplastic syndrome (MDS) progressing to acute 
      myeloid leukemia (AML) FAB M4. Cytogenetic analysis revealed an unusual 
      rearrangement between chromosomes 9 and 17, leading to a dicentric chromosome 
      with an insertion of material of unknown origin between both chromosomes. By 
      fluorescence in situ hybridization (FISH), the insertion was shown to be an 
      amplification of part of 17q, involving ERBB2, RARA, and TOP2A genes. The median 
      copy number of ERBB2, RARA, and TOP2A genes in the tumor cells was six (range: 
      4--10). Only one copy of the MPO gene at 17q21.3 was detected, suggesting a 
      deletion of the telomeric part of 17q. To our knowledge, this is the first report 
      of a 17q amplification in AML.
FAU - Martin-Subero, J I
AU  - Martin-Subero JI
AD  - Institute of Human Genetics, University Hospital Kiel, Schwanenweg 24, 24105 
      Kiel, Germany.
FAU - Harder, L
AU  - Harder L
FAU - Gesk, S
AU  - Gesk S
FAU - Schoch, R
AU  - Schoch R
FAU - Novo, F J
AU  - Novo FJ
FAU - Grote, W
AU  - Grote W
FAU - Calasanz, M J
AU  - Calasanz MJ
FAU - Schlegelberger, B
AU  - Schlegelberger B
FAU - Siebert, R
AU  - Siebert R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Isoenzymes)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - 0 (RARA protein, human)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoic Acid Receptor alpha)
RN  - 04079A1RDZ (Cytarabine)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
RN  - FTK8U1GZNX (Thioguanine)
RN  - ZS7284E0ZP (Daunorubicin)
RN  - DAT protocol 1
SB  - IM
MH  - Antigens, Neoplasm/genetics
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/therapeutic use
MH  - Cell Transformation, Neoplastic/genetics
MH  - *Chromosome Aberrations
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 17
MH  - *Chromosomes, Human, Pair 9
MH  - Cytarabine/administration & dosage
MH  - *DNA Topoisomerases, Type II/*genetics
MH  - DNA-Binding Proteins
MH  - Daunorubicin/administration & dosage
MH  - Female
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Isoenzymes/*genetics
MH  - Karyotyping
MH  - Leukemia, Myelomonocytic, Acute/drug therapy/*genetics/pathology
MH  - Metaphase
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*genetics/pathology
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Receptors, Retinoic Acid/genetics
MH  - Retinoic Acid Receptor alpha
MH  - Thioguanine/administration & dosage
EDAT- 2001/06/27 10:00
MHDA- 2001/07/20 10:01
CRDT- 2001/06/27 10:00
PHST- 2001/06/27 10:00 [pubmed]
PHST- 2001/07/20 10:01 [medline]
PHST- 2001/06/27 10:00 [entrez]
AID - S0165-4608(00)00431-3 [pii]
AID - 10.1016/s0165-4608(00)00431-3 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2001 Jun;127(2):174-6. doi: 
      10.1016/s0165-4608(00)00431-3.